Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)
Research grant utilizing PLCO bioresources for advancing cancer etiology and early detection biomarkers through biochemical and genetic analyses.
Funder: National Institutes of Health
Due Dates: June 10, 2025 (New/Renewal/Resubmission) | October 10, 2025 | February 10, 2026 | June 10, 2026 | October 9, 2026 | February 10, 2027 | June 10, 2027 | October 8, 2027
Funding Amounts: No budget cap; budgets must reflect actual project needs. Maximum project period: 5 years.
Summary: Supports research using PLCO biorepository resources to advance cancer etiology and early detection biomarker discovery and validation.
Key Information: Application must use PLCO biospecimens and include a letter confirming their availability; clinical trials are not allowed.
Description
This opportunity, offered by the National Cancer Institute (NCI) at NIH, funds research projects that utilize the unique biospecimen and data resources of the Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The goal is to advance understanding of cancer etiology and to discover or validate early detection biomarkers. Projects must leverage the PLCO biorepository, which includes high-quality, prospectively collected, serial pre-diagnostic blood samples and buccal cells, along with rich associated demographic, lifestyle, and clinical data.
Research may include, but is not limited to:
- Biochemical and genetic analyses of cancer risk
- Discovery and pivotal validation of early detection biomarkers
- Development of risk prediction models using longitudinal biomarker data
- Correlation of blood biomarkers with tumor behavior, tissue biomarkers, and clinical outcomes
- Studies on non-cancer outcomes related to aging (e.g., Alzheimer’s, osteoporosis) are also eligible
Projects that do not use PLCO biospecimens are not eligible.
